Al-Baadani Abeer M, Elzein Fatehi E, Alhemyadi Salwa A, Khan Osama A, Albenmousa Ali H, Idrees Majdy M
Department of Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Ann Thorac Med. 2019 Jul-Sep;14(3):179-185. doi: 10.4103/atm.ATM_179_18.
After the emergence of new influenza viruses, the morbidity and mortality of viral pneumonia have received a great attention.
The objective of this study is to describe the epidemiologic, clinical and laboratory changes, and outcomes of viral pneumonia caused by influenza and the Middle East respiratory syndrome-coronavirus (MERS-CoV) infections.
In a retrospective cohort study, the medical records of all patients diagnosed with viral pneumonia at Prince Sultan Military Medical City, Riyadh, Saudi Arabia, during the period from January 2012 to December 2015 were screened. Cases who were > 18 years old and were confirmed by a respiratory viral panel to have viral pneumonia either MERS-CoV or influenza viruses were included in the analysis. Sociodemographic, clinical, laboratory, and outcome data were extracted from patients' medical files. The data were analyzed descriptively and inferentially to identify the predictors of poor outcome.
A total of 448 patients with confirmed viral pneumonia were included, of those, 216 (48.2%) were caused by influenza A (non H1N1)/influenza B, 150 (33.5%) by H1N1, and 82 (18.3%) by MERS-CoV. The majority of patients presented with fever (82%), shortness of breath (64%), and flu-like symptoms (54.9%), particularly in MERS-CoV infected cases (92%). The peak incidence of viral pneumonia was in early spring and autumn. The mortality rate was 13.8%, and it was significantly higher among MERS-CoV cases. The predictors of death were age > 65 years, male gender, and associated comorbidities particularly diabetes mellitus, hypertension, and chronic kidney diseases. The number of comorbid illnesses was directly related to the increase in mortality in this group of patients.
Viral pneumonia caused by influenza and MERS-CoV carries a high mortality rate, particularly among MERS-CoV infected cases. Old age, male gender, and comorbid illnesses are predictors of poor outcome. Routine testing for newly emergent viruses is warranted for adults who have been hospitalized with pneumonia.
新型流感病毒出现后,病毒性肺炎的发病率和死亡率备受关注。
本研究旨在描述流感和中东呼吸综合征冠状病毒(MERS-CoV)感染所致病毒性肺炎的流行病学、临床和实验室变化以及结局。
在一项回顾性队列研究中,筛查了2012年1月至2015年12月期间在沙特阿拉伯利雅得苏丹王子军事医疗城被诊断为病毒性肺炎的所有患者的病历。纳入分析的病例为年龄大于18岁且经呼吸道病毒检测确诊为MERS-CoV或流感病毒所致病毒性肺炎的患者。从患者病历中提取社会人口学、临床、实验室和结局数据。对数据进行描述性和推断性分析,以确定预后不良的预测因素。
共纳入448例确诊的病毒性肺炎患者,其中216例(48.2%)由甲型流感(非H1N1)/乙型流感引起,150例(33.5%)由H1N1引起,82例(18.3%)由MERS-CoV引起。大多数患者出现发热(82%)、呼吸急促(64%)和流感样症状(54.9%),特别是在MERS-CoV感染病例中(92%)。病毒性肺炎的发病高峰在早春和秋季。死亡率为13.8%,MERS-CoV病例的死亡率显著更高。死亡的预测因素为年龄大于65岁、男性以及合并症,尤其是糖尿病、高血压和慢性肾脏病。合并症的数量与该组患者死亡率的增加直接相关。
流感和MERS-CoV所致病毒性肺炎死亡率高,尤其是在MERS-CoV感染病例中。老年、男性和合并症是预后不良的预测因素。对于因肺炎住院的成年人,有必要对新出现的病毒进行常规检测。